November 16, 2017 – DURHAM, NC: A Phase 1 clinical trial leveraging the re-engineered polio virus is now open for enrollment to children 12 years and older at the Preston Robert Tisch Brain Tumor Center, Duke University Medical Center. After years of following the progress of this promising therapy against adult glioblastoma and working with…
Lorlatinib may prove effective for the treatment of neuroblastoma. Solving Kids Cancer is leading an international effort of like-minded nonprofits to provide nearly $400,000 of collaborative funding for an innovative clinical trial to bring a potentially life-saving therapy to kids.
Solving Kids` Cancer was the first charity to ever go against the UK healthcare system without a pharmaceutical company involved. As a result, the National Institute for Health and Care Excellence (NICE) recently announced that it has upheld SKC`s appeal against the Institutes decision not to recommend dinutuximab for treating high-risk neuroblastoma.
November 17, 2016
Next Generation Personalized Neuroblastoma Therapy gives hope to children with relapse or refractory disease.
Children with high grade brain tumors will soon be able to receive cutting-edge onocolytic virus therapy.
August 24, 2016
Collaborative Research Funding Helps to Advance Innovative New Treatments for Pediatric Brain Tumors
SKC challenged NICE on their decision to deny children the only drug ever specifically developed against neuroblastoma. SKC provided logical arguments against their assessment of cost and efficacy, and championed the plight of these innocent and vulnerable children.
The 6th Annual Spring Celebration was held on June 8 at 583 Park Avenue in New York City. 300 guests attended the event and helped raise $300,000 during the live auction to create three new clinical trials using combination PD-1 inhibitors for children with deadly brain tumors and neuroblastoma.